1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Anavex Reveals Positive Phase III Data In Rett Syndrome But A Surprise Endpoint

 
• By Jessica Merrill

The endpoint used in the AVATAR trial was different than the one investors had expected; management said the change was made to satisfy the US FDA.

direction
Anavex took a different direction with a Phase III trial • Source: Alamy

Anavex Life Sciences Corp. announced positive Phase III data from a clinical trial testing blarcamesine (Anavex 2-73) in patients with the debilitating neurodevelopmental disorder Rett syndrome, but the endpoint used in the study was different from the one investors had expected – a change that management said was based on guidance from the US Food and Drug Administration.

The late change in the design of the trial raised questions about the data and led to a stock decline following the 1 February announcement. The company's stock closed down...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Therapy Areas

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.